PepGen more than doubles as muscle disease drug tops expectations
PEPG•PepGen shares rose 124% premarket after mid-stage trial results for its experimental myotonic dystrophy type 1 drug exceeded expectations. The company reported a 46.5% correction of faulty muscle cell processes at the 10 mg/kg dose and expects results from a higher-dose cohort in the first half of 2027.
1. Trial results
PepGen said PGN-EDODM1 achieved a 46.5% correction of faulty muscle cell processes at the 10 mg/kg dose. Patients also showed improvements in hand grip strength, walking speed and overall mobility.
2. Safety and next results
PepGen said the drug was generally well tolerated, with no serious or severe adverse events. A higher-dose cohort is fully enrolled, and the company expects results in the first half of 2027.
